CY1109005T1 - Φαρμακευτικη συνθεση η οποια περιλαμβανει ενα ανδρογονο - Google Patents

Φαρμακευτικη συνθεση η οποια περιλαμβανει ενα ανδρογονο

Info

Publication number
CY1109005T1
CY1109005T1 CY20071101504T CY071101504T CY1109005T1 CY 1109005 T1 CY1109005 T1 CY 1109005T1 CY 20071101504 T CY20071101504 T CY 20071101504T CY 071101504 T CY071101504 T CY 071101504T CY 1109005 T1 CY1109005 T1 CY 1109005T1
Authority
CY
Cyprus
Prior art keywords
composition
androgen
pharmaceutical composition
composition containing
enhancer
Prior art date
Application number
CY20071101504T
Other languages
English (en)
Inventor
Robert Gyurik
Original Assignee
Cpex Pharmaceuticals, Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=29251138&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1109005(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Cpex Pharmaceuticals, Inc filed Critical Cpex Pharmaceuticals, Inc
Publication of CY1109005T1 publication Critical patent/CY1109005T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/06—Anabolic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/26—Androgens

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Diabetes (AREA)
  • Reproductive Health (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Gynecology & Obstetrics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)

Abstract

Μια φαρμακευτική σύνθεση η οποία περιλαμβάνει: (Α) ανδρογόνο· (Β) έναν κυκλικό ενισχυτή του τύπου που χρησιμοποείται στις συνθέσεις και μεθόδους που αξιώνονται από το Δίπλωμα Ευρεσιτεχνίας των ΗΠΑ Νο. 5,023,252 του Hsieh· και (C) έναν παράγοντα αύξησης του ιξώδους· περιλαμβάνοντας, για παράδειγμα, μια σύνθεση στην οποία ο κυκλικός ενισχυτής είναι ένας μακροκυκλικός εστέρας ή μια μακροκυκλική κετόνη· τη χρήση της σύνθεσης για την αντιμετώπιση μιας κατάστασης, για παράδειγμα, ανδρικού υπογοναδισμού, σε έναν ασθενή μέσω εφαρμογής της σύνθεσης στη μεμβράνη του ασθενούς· και μια μέθοδος παρασκευής της σύνθεσης.
CY20071101504T 2002-04-19 2007-11-26 Φαρμακευτικη συνθεση η οποια περιλαμβανει ενα ανδρογονο CY1109005T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US37410302P 2002-04-19 2002-04-19
EP03726373A EP1425019B1 (en) 2002-04-19 2003-04-21 Pharmaceutical composition comprising an androgen

Publications (1)

Publication Number Publication Date
CY1109005T1 true CY1109005T1 (el) 2014-07-02

Family

ID=29251138

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20071101504T CY1109005T1 (el) 2002-04-19 2007-11-26 Φαρμακευτικη συνθεση η οποια περιλαμβανει ενα ανδρογονο

Country Status (30)

Country Link
US (21) US7320968B2 (el)
EP (2) EP1741433B1 (el)
JP (1) JP2005519985A (el)
KR (2) KR100952786B1 (el)
CN (2) CN1662243B (el)
AR (2) AR039644A1 (el)
AT (1) ATE371456T1 (el)
AU (1) AU2003228612B2 (el)
BR (1) BR0309390A (el)
CA (1) CA2470200C (el)
CY (1) CY1109005T1 (el)
DE (1) DE60315939T2 (el)
DK (1) DK1425019T3 (el)
EA (1) EA009839B1 (el)
EG (1) EG24882A (el)
ES (2) ES2292964T3 (el)
HK (3) HK1082682A1 (el)
IL (1) IL164547A (el)
IS (2) IS2667B (el)
LT (1) LT5235B (el)
LV (1) LV13303B (el)
MX (1) MXPA04010311A (el)
MY (1) MY139721A (el)
NO (1) NO335864B1 (el)
NZ (1) NZ535970A (el)
PL (1) PL213976B1 (el)
SA (1) SA03240158B1 (el)
TW (1) TWI362932B (el)
WO (1) WO2003088974A1 (el)
ZA (1) ZA200408422B (el)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030139384A1 (en) * 2000-08-30 2003-07-24 Dudley Robert E. Method for treating erectile dysfunction and increasing libido in men
US6503894B1 (en) * 2000-08-30 2003-01-07 Unimed Pharmaceuticals, Inc. Pharmaceutical composition and method for treating hypogonadism
US20040002482A1 (en) * 2000-08-30 2004-01-01 Dudley Robert E. Androgen pharmaceutical composition and method for treating depression
US20040092494A9 (en) * 2000-08-30 2004-05-13 Dudley Robert E. Method of increasing testosterone and related steroid concentrations in women
US20040072810A1 (en) * 2001-11-07 2004-04-15 Besins International Belgique Pharmaceutical composition in the form of a gel or a solution based on dihydrotestosterone, process for preparing it and uses thereof
MY139721A (en) * 2002-04-19 2009-10-30 Cpex Pharmaceuticals Inc Pharmaceutical composition
US20040259852A1 (en) * 2003-06-18 2004-12-23 White Hillary D. Trandsdermal compositions and methods for treatment of fibromyalgia and chronic fatigue syndrome
US8883769B2 (en) * 2003-06-18 2014-11-11 White Mountain Pharma, Inc. Methods for the treatment of fibromyalgia and chronic fatigue syndrome
JP2008512425A (ja) * 2004-09-09 2008-04-24 ラボラトワール ブザン アンテルナスィヨナル 透過促進剤としてのプロピレングリコールを含むテストステロンゲル
EP1634583A1 (en) * 2004-09-09 2006-03-15 Laboratoires Besins International Testosterone gels comprising propylene glycol as penetration enhancer
US20070088012A1 (en) * 2005-04-08 2007-04-19 Woun Seo Method of treating or preventing type-2 diabetes
TR201815853T4 (tr) 2005-10-12 2018-11-21 Besins Healthcare Sarl Hipogonadizmin tedavisinde kullanıma yönelik geliştirilmiş testosteron jeli.
MX2010012261A (es) * 2008-05-09 2011-04-07 Tolmar Inc Proguanil para tratar enfermedades de la piel/mucosa.
WO2009149368A1 (en) * 2008-06-05 2009-12-10 Cpex Pharmaceuticals, Inc. Nasal formulations of insulin
WO2011049776A1 (en) * 2009-10-22 2011-04-28 Cpex Pharmaceuticals, Inc. Therapeutically effective preparations of insulin
AU2011329782A1 (en) 2010-11-18 2013-06-20 White Mountain Pharma, Inc. Methods for treating chronic or unresolvable pain and/or increasing the pain threshold in a subject and pharmaceutical compositions for use therein
US20130040923A1 (en) 2011-05-13 2013-02-14 Trimel Pharmaceuticals Corporation Intranasal lower dosage strength testosterone gel formulations and use thereof for treating anorgasmia or hypoactive sexual desire disorder
US9757388B2 (en) 2011-05-13 2017-09-12 Acerus Pharmaceuticals Srl Intranasal methods of treating women for anorgasmia with 0.6% and 0.72% testosterone gels
US20130045958A1 (en) 2011-05-13 2013-02-21 Trimel Pharmaceuticals Corporation Intranasal 0.15% and 0.24% testosterone gel formulations and use thereof for treating anorgasmia or hypoactive sexual desire disorder
KR20210135003A (ko) * 2011-05-15 2021-11-11 에이세러스 바이오파마 인크. 비내용 테스토스테론 바이오-접착제 겔 제형 및 남성의 성선기능저하증을 치료하기 위한 그의 용도
US10568905B2 (en) * 2012-02-14 2020-02-25 Metabolic Therapy Inc. Pharmaceutical composition and method for treating retinal neurodegeneration
EP2833944A4 (en) 2012-04-06 2016-05-25 Antares Pharma Inc ADMINISTRATION OF TESTOSTERONE COMPOSITIONS BY NEEDLE-SUPPORTED NOZZLE INJECTION
IN2015KN00677A (el) 2012-09-20 2015-07-17 Gkn Armstrong Wheels Inc
US11744838B2 (en) 2013-03-15 2023-09-05 Acerus Biopharma Inc. Methods of treating hypogonadism with transnasal testosterone bio-adhesive gel formulations in male with allergic rhinitis, and methods for preventing an allergic rhinitis event
US8785426B1 (en) * 2013-12-13 2014-07-22 Upsher-Smith Laboratories, Inc. Testosterone gel compositions and related methods
US20170014417A1 (en) 2015-07-14 2017-01-19 Lipp Life Sciences Llc Pharmaceutical administration system for the transdermal application of vardenafil
WO2019089942A1 (en) * 2017-11-02 2019-05-09 Rick Coulon Formulations for use in the transdermal delivery of proteasome inhibitors
CN112666197B (zh) * 2020-11-29 2022-11-04 山东大学 一种用于tbm的岩渣石英含量测试系统及方法

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3989815A (en) * 1975-06-19 1976-11-02 Nelson Research & Development Company Novel N-bis-azacyclopentan-2-onyl alkanes
BE843140A (fr) * 1975-06-19 1976-10-18 Aazacycloalcan-2-ones 1-substituees et compositions pharmaceutiques contenant ces composes a titre d'excipients
US3989816A (en) * 1975-06-19 1976-11-02 Nelson Research & Development Company Vehicle composition containing 1-substituted azacycloheptan-2-ones
US4405616A (en) * 1975-06-19 1983-09-20 Nelson Research & Development Company Penetration enhancers for transdermal drug delivery of systemic agents
US3991203A (en) * 1975-06-19 1976-11-09 Nelson Research & Development Company Vehicle composition containing 1-substituted azacyclopentan-2-ones
US4316893A (en) * 1975-06-19 1982-02-23 Nelson Research & Development Co. Vehicle composition containing 1-substituted azacycloalkan-2-ones
US4444762A (en) * 1980-04-04 1984-04-24 Nelson Research & Development Company Vehicle composition containing 1-substituted azacyclopentan-2-ones
US4424210A (en) * 1980-04-04 1984-01-03 Nelson Research & Development Company Vehicle composition containing 1-substituted azacycloalkan-2-ones
US4423040A (en) * 1980-04-04 1983-12-27 Nelson Research & Development Company Vehicle composition containing 1-substituted azacyclohexan-2-ones
US4415563A (en) * 1980-04-04 1983-11-15 Nelson Research & Development Company Vehicle composition containing 1-substituted azacyclononan-2-ones
US5731303A (en) 1985-12-04 1998-03-24 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery compositions
US5023252A (en) * 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
US5270346A (en) 1986-01-31 1993-12-14 Whitby Research, Inc. Penetration enhancers for transdermal delivery of systemic agents
US4992422A (en) * 1986-01-31 1991-02-12 Whitby Research, Inc. Compositions comprising 1-substituted azacycloalkanes
US4801586A (en) 1986-04-23 1989-01-31 Nelson Research & Development Co. Penetration enhancers for transdermal delivery of systemic agents
US4879275A (en) 1987-09-30 1989-11-07 Nelson Research & Development Co. Penetration enhancers for transdermal delivery of systemic agent
US5019395A (en) * 1988-03-08 1991-05-28 Warner-Lambert Company Compositions with enhanced penetration
US5676968A (en) * 1991-10-31 1997-10-14 Schering Aktiengesellschaft Transdermal therapeutic systems with crystallization inhibitors
US6190691B1 (en) * 1994-04-12 2001-02-20 Adolor Corporation Methods for treating inflammatory conditions
GB9516268D0 (en) * 1995-08-08 1995-10-11 Danbiosyst Uk Compositiion for enhanced uptake of polar drugs from the colon
DE19619045C1 (de) * 1996-05-02 1997-11-13 Jenapharm Gmbh Verwendung von Kombinationspräparaten zur Behandlung hypogonadaler Männer sowie Männern mit Hypophysenerkrankungen
US5980898A (en) * 1996-11-14 1999-11-09 The United States Of America As Represented By The U.S. Army Medical Research & Material Command Adjuvant for transcutaneous immunization
US6019997A (en) * 1997-01-09 2000-02-01 Minnesota Mining And Manufacturing Hydroalcoholic compositions for transdermal penetration of pharmaceutical agents
DE19701949A1 (de) * 1997-01-13 1998-07-16 Jenapharm Gmbh Transdermales therapeutisches System
ES2229473T3 (es) * 1997-01-30 2005-04-16 Novartis Ag Composiciones farmaceuticas sin aceite que contienen ciclosporina a.
DE19709960A1 (de) * 1997-03-11 1998-09-24 Aesculap Ag & Co Kg Verfahren und Vorrichtung zur präoperativen Bestimmung der Positionsdaten von Endoprothesenteilen
US5968919A (en) * 1997-10-16 1999-10-19 Macrochem Corporation Hormone replacement therapy drug formulations for topical application to the skin
IL136042A (en) * 1997-11-10 2005-12-18 Cellegy Pharma Inc Alcohol-containing composition for topical application
US6980952B1 (en) * 1998-08-15 2005-12-27 Texas Instruments Incorporated Source normalization training for HMM modeling of speech
EP1031564A1 (en) * 1999-02-26 2000-08-30 Klinge Pharma GmbH Inhibitors of cellular nicotinamide mononucleotide formation and their use in cancer therapy
FR2801507B1 (fr) * 1999-11-30 2003-06-27 Pf Medicament Dispositif transdermique auto-adhesif comprenant un reservoir et une matrice contenant le meme principe actif, son procede de preparation et ses utilisations
CN1376146B (zh) * 1999-12-08 2011-04-06 法马西亚公司 提高了生物利用率的雪列柯西的固态形式
US6495124B1 (en) 2000-02-14 2002-12-17 Macrochem Corporation Antifungal nail lacquer and method using same
US7198801B2 (en) * 2000-08-03 2007-04-03 Antares Pharma Ipl Ag Formulations for transdermal or transmucosal application
ATE355854T1 (de) * 2000-08-03 2007-03-15 Antares Pharma Ipl Ag Neue zusammensetzung zur transdermalen und/oder transmukosalen wirkstoffanwendung mit geeignetem therapeutischen spiegel
US20040198706A1 (en) * 2003-03-11 2004-10-07 Carrara Dario Norberto R. Methods and formulations for transdermal or transmucosal application of active agents
US6503894B1 (en) 2000-08-30 2003-01-07 Unimed Pharmaceuticals, Inc. Pharmaceutical composition and method for treating hypogonadism
ES2423899T3 (es) * 2000-08-30 2013-09-25 Unimed Pharmaceuticals, Llc Método para aumentar las concentraciones de testosterona y esteroides relacionados en las mujeres
US20030139384A1 (en) * 2000-08-30 2003-07-24 Dudley Robert E. Method for treating erectile dysfunction and increasing libido in men
SI1315502T1 (sl) 2000-08-30 2010-07-30 Unimed Pharmaceuticals Llc Postopek za zdravljenje erektilne disfunkcije in za poveäśanje libida pri moĺ kih
US20040092494A9 (en) * 2000-08-30 2004-05-13 Dudley Robert E. Method of increasing testosterone and related steroid concentrations in women
US20040002482A1 (en) * 2000-08-30 2004-01-01 Dudley Robert E. Androgen pharmaceutical composition and method for treating depression
WO2002055020A2 (en) * 2000-12-11 2002-07-18 Testocreme Llc Topical testosterone formulations and associated methods
HUP0600234A3 (en) * 2000-12-22 2011-04-28 August Wolff Gmbh & Co Dr Gel composition containing at least one steroid and trans-scrotal application of the composition for the treatment of hypogonadism
WO2002089849A1 (en) * 2001-05-07 2002-11-14 Corium International Compositions and delivery systems for administration of a local anesthetic agent
US20030027804A1 (en) * 2001-06-27 2003-02-06 Van Der Hoop Roland Gerritsen Therapeutic combinations for the treatment of hormone deficiencies
US6980852B2 (en) * 2002-01-25 2005-12-27 Subqiview Inc. Film barrier dressing for intravascular tissue monitoring system
AU2003228314C1 (en) 2002-03-15 2009-03-26 Besins Healthcare Luxembourg Sarl Androgen pharmaceutical composition and method for treating depression
MY139721A (en) * 2002-04-19 2009-10-30 Cpex Pharmaceuticals Inc Pharmaceutical composition
US20040259784A1 (en) * 2003-06-18 2004-12-23 White Hillary D. Compositions and methods for treatment of muscle pain and muscle wasting

Also Published As

Publication number Publication date
NZ535970A (en) 2006-12-22
US20090118252A1 (en) 2009-05-07
US8063029B2 (en) 2011-11-22
PL372083A1 (en) 2005-07-11
EP1425019B1 (en) 2007-08-29
EP1425019A1 (en) 2004-06-09
EG24882A (en) 2010-12-01
US7608606B2 (en) 2009-10-27
US20080103120A1 (en) 2008-05-01
US20080108590A1 (en) 2008-05-08
LV13303B (en) 2006-08-20
US20050192260A1 (en) 2005-09-01
US20160129016A1 (en) 2016-05-12
HK1167332A1 (en) 2012-11-30
BR0309390A (pt) 2005-02-09
CA2470200A1 (en) 2003-10-30
CN102357098A (zh) 2012-02-22
PL213976B1 (pl) 2013-05-31
TWI362932B (en) 2012-05-01
DK1425019T3 (da) 2008-02-04
IS2667B (is) 2010-08-15
ES2292964T3 (es) 2008-03-16
US20210308145A1 (en) 2021-10-07
AR087484A2 (es) 2014-03-26
KR20050011753A (ko) 2005-01-29
ES2399900T3 (es) 2013-04-04
WO2003088974A1 (en) 2003-10-30
US20090118250A1 (en) 2009-05-07
US20090118251A1 (en) 2009-05-07
CN1662243A (zh) 2005-08-31
HK1098386A1 (en) 2007-07-20
US20150283153A1 (en) 2015-10-08
US7935690B2 (en) 2011-05-03
US20090192132A1 (en) 2009-07-30
US20100081640A1 (en) 2010-04-01
IS8870A (is) 2010-01-06
MXPA04010311A (es) 2005-02-03
US20140343025A1 (en) 2014-11-20
US7608607B2 (en) 2009-10-27
AU2003228612A1 (en) 2003-11-03
SA03240158B1 (ar) 2007-02-17
US20130059828A1 (en) 2013-03-07
LT5235B (lt) 2005-06-27
ZA200408422B (en) 2006-06-28
KR100977896B1 (ko) 2010-08-24
EP1741433A1 (en) 2007-01-10
LT2004101A (en) 2005-04-25
US20090192131A1 (en) 2009-07-30
DE60315939T2 (de) 2008-05-21
CN102357098B (zh) 2014-12-17
AU2003228612B2 (en) 2006-05-04
US20090124590A1 (en) 2009-05-14
IS7535A (is) 2004-11-17
EA009839B1 (ru) 2008-04-28
US20080275012A1 (en) 2008-11-06
IL164547A0 (en) 2005-12-18
US20130281416A1 (en) 2013-10-24
TW200408397A (en) 2004-06-01
US20090124589A1 (en) 2009-05-14
US20090131387A1 (en) 2009-05-21
US7608609B2 (en) 2009-10-27
CN1662243B (zh) 2011-10-26
CA2470200C (en) 2005-07-26
ATE371456T1 (de) 2007-09-15
US7320968B2 (en) 2008-01-22
IL164547A (en) 2011-01-31
AR039644A1 (es) 2005-03-02
KR20090079266A (ko) 2009-07-21
EA200401410A1 (ru) 2005-04-28
NO335864B1 (no) 2015-03-09
DE60315939D1 (de) 2007-10-11
JP2005519985A (ja) 2005-07-07
US8178518B2 (en) 2012-05-15
US20210308146A1 (en) 2021-10-07
HK1082682A1 (en) 2006-06-16
US20080275013A1 (en) 2008-11-06
KR100952786B1 (ko) 2010-04-14
EP1741433B1 (en) 2012-11-07
US7608608B2 (en) 2009-10-27
EP1425019A4 (en) 2004-11-17
US7608605B2 (en) 2009-10-27
US7608610B2 (en) 2009-10-27
MY139721A (en) 2009-10-30
IS2946B (is) 2016-05-15
NO20045019L (no) 2005-01-14

Similar Documents

Publication Publication Date Title
CY1109005T1 (el) Φαρμακευτικη συνθεση η οποια περιλαμβανει ενα ανδρογονο
CY1106386T1 (el) Υποκατεστημενα παραγωγα 3-πυρρολιδιν-ινδολης
CY1113039T1 (el) Ηλεκτρικο και μηλονικο αλας τρανς-4-(1r,3s)-6-χλωρο-3-φαινυλινδαν-1-υλο)-1,2,2-τριμεθυλοπιπεραζινης και η χρηση ως φαρμακο
CY1118195T1 (el) Φαρμακευτικο στερεο στοματικο παρασκευασμα αριπιπραζολης και μεθοδοι για την παρασκευη αυτου
CL2003002767A1 (es) Composicion oral que comprende una pelicula que contiene un material funcional, en un vehiculo, util para el cuidado oral.
CY1115117T1 (el) Παραγωγα υποκατεστημενων οξαζολιδινονων και η χρηση τους ως αναστολεις παραγοντα χα
CY1113809T1 (el) Μακροκυκλικα καρβοξυλικα οξεα και ακυλοσουλφοναμιδικες ενωσεις ως αναστολεις της αντιγραφης του hcv
CY1107294T1 (el) Τοπικη συνθεση η οποια περιεχει τουλαχιστον μια βιταμινη d ή ενα αναλογο της βιταμινης d και τουλαχιστον ενα κορτικοστεροειδες
AR011116A1 (es) Compuesto derivado de n-hidroxi-beta-sulfonil propionamida y composicion farmaceutica que lo contiene
RS49756B (sr) Primena ksenona ili smeša ksenonskog gasa za proizvodnju farmaceutskog preparata za lečenje neurointoksikacija
CY1106682T1 (el) Ενωση λακταμης
CY1110907T1 (el) Φαρμακευτικη συνθεση και μεθοδος για την θεραπεια υπογοναδισμου
RS51764B (en) TRANSDERMAL PHARMACEUTICAL COMPOSITION
ATE267822T1 (de) Verfahren zur herstellung von luteolin und luteolin-derivaten
ATE536859T1 (de) Maca-extrakt und diesen extrakt enthaltende kosmetische zusammensetzung
NO20055612L (no) Anti-inflammatoriske fosfonatforbindelser
DE60133817D1 (de) Verfahren zur herstellung von aplidin und neue antitumoralen derivate, verfahren zu deren herstellung und zu deren verwendung
ATE401304T1 (de) Kationisch substituierte diphenylazetidinone, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
ATE388697T1 (de) Sprühbare zusammensetzung zur verabreichung von vitamin d derivaten
CY1107231T1 (el) Υποκατεστημενα παραγωγα 4-αμινοκυκλοεξανολης
BRPI0401182A (pt) Composição, processo para colorir as fibras queratìnicas humanas, processo para colorir pele escura, dispositivo com vários compartimentos e uso de uma composição
ATE252365T1 (de) Zusammenstzungen enthaltend organosiloxan-harze zur freisetzung von mundpflegewirkstoffen
CY1105345T1 (el) Φαινυλαλκινια
HUP0200055A2 (hu) 16-Hidroxi-ösztratriének és ezeket tartalmazó gyógyszerkészítmények
ATE527377T1 (de) Erstellung von genexpressionprofilen aus ffpe- proben